The LeFrak Center for Robotic Surgery is home to a partnership between the most technologically-advanced surgical robots and the most experienced and dedicated surgical team. The Center is led by the internationally renowned surgeon, Dr. Jim C.
Dr. Christopher Barbieri completed both his Urology Residency and Urologic Oncology Fellowship at Weill Cornell Medical College. He received his undergraduate degree from Dartmouth College and then attended Vanderbilt University School of Medicine, where he obtained both his MD and PhD degrees. Dr. Barbieri's research interests include using genomic data to define distinct molecular subclasses of urologic malignancy, with a particular focus on prostate cancer.
Joseph J. Del Pizzo, M.D. is the E. Darracott Vaughan Jr., Professor of Urology and the Board Certified Director of Laparoscopic and Robotic Surgery for the Department of Urology at Weill Cornell Medicine. He joined the surgical staff at The New York Presbyterian Hospital in 2000 after serving as a clinical fellow in Laparoscopy and Minimally Invasive Urology.
Urologic oncology is a multidisciplinary field that incorporates innovative surgical technology, systemic treatments such as chemotherapy, as well as a focused research effort. As a Professor of Urology and the Clinical Director of Urologic Oncology, I continually interact with colleagues in the areas of medical oncology, radiation oncology, and pathology, among others, in order to provide the most comprehensive and innovative care for our patients with prostate, bladder, kidney and testicular cancer.
Dr. Jim Hu is a urologic oncologist with his undergraduate degree in Economics, his Master’s in Public Health in HealtPolicy and Management from Johns Hopkins University, and his Medical Degree from Baylor College of Medicine. He completed his Urology Residency at the David Geffen School of Medicine at UCLA and his Robotic Surgery/Urologic Oncology Fellowship in 2004 at City of Hope National Medical Center.
In 2015, it is estimated that 8,400 U.S. men were diagnosed with testis cancer and 380 men died from testis cancer. Testis cancer is most commonly diagnosed in the second and third decade of life, with the average age of diagnosis being 33 years. For unknown reasons, testis cancer is becoming more prevalent in the U.S. and elsewhere.
Men are three to four times more likely than women to be diagnosed with bladder cancer. The most common type of bladder cancer is transitional cell carcinoma, comprising 90% of all bladder cancers. Transitional cell carcinomas are staged according to the depth of bladder wall invasion, which also has bearing on treatment options. Superficial transitional cell carcinomas are in the lining of the bladder and have not invaded the deeper bladder muscle wall, whereas muscle invasive cancers have penetrated this layer and are more likely to spread.
Dr. Schlegel is an internationally acclaimed expert in the treatment of male infertility, especially the interface of male factor treatment with assisted reproductive techniques. His work has also clarified the importance of hormonal therapy, sperm analysis and genetic studies in the evaluation of men with infertility. He was awarded the 1996 Established Clinician Award by The European Society for Human Reproduction and Embryology.
The Brady Urologic Health Center is located within an 8,000 square foot suite on the ninth floor of the Starr Pavilion at Weill Cornell Medicine/New York-Presbyterian Hospital and is composed of a close-knit team of physicians, working together to provide treatment for the broad spectrum of urologic conditions.